We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

View the slides and replay for the IMF’s Post ASCO/EHA/IMWG Recap Teleconference!
Please join Brian G.M. Durie, MD as he explains what's new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG).

DARZALEX™ (daratumumab) Approved by Health Canada as the First Human Anti-CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma
Janssen Inc. announces Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD. Health Canada approved this product on the condition that Janssen Inc. carries out confirmatory trials to verify the clinical benefit of DARZALEX™.

FDA Approves New Kyprolis® (carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP)—a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma. As of July 3, 2016, CHMP approved Kyprolis in combination with dexamethasone alone to treat adult patients who have received at least one prior therapy.

IMF Educates on Dangers of Limiting Access to Myeloma Treatment Options
Robin Tuohy, IMF Senior Director of Support Groups, and her husband Michael Tuohy, a 16-year myeloma survivor and active patient advocate, appeared at a congressional briefing in Washington DC this week. They shared the perspective of patients and caregivers on the myeloma treatment guidelines that were recently proposed by the Institute for Clinical and Economic Review (ICER). The briefing was organized by the Partnership to Improve Patient Care (PIPC). Robin spoke of her family’s journey in coping with Michael’s illness. She also addressed how the proposals recommended in the ICER Report to the Center for Medicare and Medicaid Services Part B Demonstration Project could negatively impact patients

Dr. Brian Durie: "ICER Blinks and Patients Benefit"
IMF Chairman Dr. Brian Durie calls the much-awaited Final Report from the Institute for Clinical and Economic Review (ICER) “less of a report than an admission that they do not have the expertise to adequately assess the complexities of new myeloma therapies.” In his blog this week, Dr. Durie notes that the report defers to the expertise of both doctors and patient advocates, and, importantly, that the International Myeloma Working Group has already launched an inclusive project to create treatment guidelines that can transform the cost/payer landscape.

Pre-EHA Chinese Hematologist Round Table

IMF in cooperation with Xian-Janssen (XJP) is hosting the Pre-EHA Chinese Hematologists Round Table at the Hotel Scandic Copenhagen in Copenhagen, Denmark.  


Robin Tuohy's testimony at CEPAC on Treatment Options for Relapsed and Refractory Myeloma

On May 26, 2016, the International Myeloma Foundation’s Senior Director of Support Groups and spouse of Michael Tuohy, a sixteen-year myeloma survivor, testified at the Comparative Effectiveness Public Advisory Council’s Public Meeting (CEPAC) on Treatment Options for Relapsed and Refractory Myeloma. In her compelling testimony, Robin shared how her husband Michael’s survival as a myeloma patient may not have been possible without access to a clinical trial, an oral therapy regimen, he has been on for the past eleven years. She pointed out, “Today we are able to treat myeloma in sequence and in combination that reflects our individual disease markers, chromosomal abnormalities, and yes, even side-effect management and quality of life choices. I’ll say that again:  choices!” She urged the Institute of Clinical and Economic Review (ICER), that while their recent report was “well-intended,” when it comes to patient care, “This is a very slippery slope that should not give anyone leverage to limit or deny access to treatment.” 


The IMWG Conference Series "Making Sense of Treatment"
7th IMWG Summit | June 9, 2016

Drs. Brian GM Durie, Joseph Mikhael,Paul Richardson, and Maria Victoria Mateos discusses the latest news and trends in the treatment of Multiple Myeloma.


Living Well with Myeloma:
What you Need to Know to Overcome Side Effects from Novel Therapies

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, OH  

Kevin Brigle, PhD, NP
VCUHS Massey Cancer Center
Richmond, VA  


International Myeloma Foundation Brings Together 100 of the World’s Top Myeloma Experts June 7-9, 2016 in Copenhagen for 7th Annual Summit

Addressing Rising Cost of Myeloma Treatments to Be a Key Focus


previous     next      view all